BAGNEUX, France, June 10, 2014 (GLOBE NEWSWIRE) -- DBV Technologies (Euronext: DBV - ISIN: FR0010417345), creator of Viaskin®, a new paradigm for the treatment of allergies, presented today robust preclinical data at the 2014 European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Copenhagen, Denmark. The data presented provides DBV with a better understanding of Viaskin®'s mechanism of action. It also further confirms epicutaneous immunotherapy's ability (EPIT) to modulate over time immune responses due to a powerful T cell (Treg) induction effect in allergic patients. The data presented at EAACI validates the positioning of Viaskin® in the treatment of allergic patients.
A total of three oral and two poster presentations were communicated at the congress. During a specific congress session, " AIT (Allergy Immunotherapy) mechanisms" , Dr. Vincent Dioszeghy, immunology researcher at DBV, showed the tropism for the digestive system of EPIT-induced Tregs, which possess some homing receptors specific to the gut. This property, much more evidenced with EPIT than any other classical specific immunotherapy, reinforces the relevance of Viaskin® in the treatment of food allergy. In a second presentation, Dr. Vincent Dioszeghy's showed that the therapeutic effect induced by EPIT was sustained even after discontinuation of epicutaneous immunotherapy. This data was further supported by the presentation of Dr. Lucie Mondoulet', DBV's Head of Research. In Dr. Lucie Mondoulet's study, strong epigenetic modulation was observed during the course of epicutaneous immunotherapy, most probably explaining the sustainability of the immune response even after discontinuation of EPIT. Dr. Lucie Mondoulet also described the protective effect of the treatment on subsequent sensitizations, thereby demonstrating the ability of EPIT to influence the course of the allergic march. These findings confirm the strong potential of this new pathway of immunotherapy.
During a separate oral session, Dr. Leticia Tordesillas from Pr. Hugh Sampson and Dr. Cecilia Berin' team at Mount Sinai Hospital in New York, US, compared the mechanism of action of DBV's epicutaneous immunotherapy versus oral immunotherapy, showing that only the protective effect of EPIT could prevent anaphylaxis after discontinuation of treatment.
In parallel to the Congress, in the May issue of Clinical & Experimental Allergy, the publication of "The regulatory T cells induction by Epicutaneous immunotherapy is sustained and mediates long term protection from eosinophilic disorders in peanut sensitized mice" (CEA, May 2014, Vol. 44 Issue 6) by Dr. Vincent Dioszeghy provides new data on the mechanism of action of Viaskin®, highlighting its strong induction of regulatory T cells. This article has been awarded the Editor's Choice.
All abstracts are available on the EAACI website and DBV Technologies' website.
About DBV Technologies
DBV Technologies is opening up a decisive new approach to the treatment of allergy - a major public health issue that is constantly increasing in prevalence. Food allergies represent a true handicap in everyday life for millions of people and thus constitute a major unmet medical need. DBV Technologies has developed a unique, proprietary, worldwide-patented technology for administering an allergen to intact skin and avoiding massive transfer to the blood. The Viaskin® technology combines efficacy and safety as part of a treatment that seeks to improve the patient's tolerability of peanut and thus considerably lower the risk of a systemic, allergic reaction in the event of accidental exposure to the allergen. The company's significant development program has taken this revolutionary method through to the industrial stage in Europe, initially. The product's clinically proven safety of use enables the application of effective desensitization techniques (the efficacy of which is acknowledged worldwide) in the most severe forms of the allergy. DBV Technologies is focusing on food allergies (milk and peanut) for which there are currently no effective treatments. It has developed two products: Viaskin® Peanut and Viaskin® Milk. The clinical development program for Viaskin® Peanut has received Fast Track designation from the US Food and Drug Administration. The company will subsequently develop a Viaskin® patch for young children with house dust mite allergy - a true public health issue because this pathology is one of the main risk factors for childhood asthma. DBV Technologies shares are traded on segment C of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345).
For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
CAUTION: Viaskin® is not approved for sale in the USA.
Forward Looking Statement
The forward-looking statements, objectives and targets contained herein are based on the Company's management strategy, current views and assumptions. Such statements involve known and unknown risks and uncertainties that may cause actual results, performance or events to differ materially from those anticipated herein. Furthermore, the Research and Development process involves several stages each of which involve the substantial risk that the Company may fail to achieve its objectives and be forced to abandon its efforts with regards to a product in which it has invested significant sums. Therefore, the Company cannot be certain that favorable results obtained during pre-clinical trials will be confirmed subsequently during clinical trials, or that the results of clinical trials will be sufficient to demonstrate the safe and effective nature of the product concerned. DBV technologies' business is subject to the risk factors outlined in its registration documents filed with the French Autorité des Marchés Financiers.
DBV Technologies Contacts
| David Schilansky Chief Financial Officer Tel. : +33(0)1 55 42 78 75 david.schilansky@dbv-technologies.com |
Susanna Mesa
VP Finance, US Investor Relations & Strategy
Tel. : +1 917-346-3447
susanna.mesa@dbv-technologies.com
DBV IR and Media Contacts
Nathalie Donne
Director, Business Development & Corporate Communications
Tel. : +33(0)1 55 42 78 72
nathalie.donne@dbv-technologies.com
Todd James
U.S. Investor Relations
The Trout Group
Tel. : +1 646-378-2926
tjames@troutgroup.com
Brad Miles
Media Relations
BMC Communications
Tel. : +1 646-513-3125
brad@bmccommunications.com
Scientific Communications at the EAACI Congress http://hugin.info/156437/R/1791777/616484.pdf
HUG#1791777
